The perspective of anti-HER2 therapy for HER2 positive breast cancer

被引：0
|
作者：
Iwata, Hiroji [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISY3-3
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [21] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [22] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    [J]. INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [23] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    [J]. Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [24] Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts
    Barbieri, E.
    Piacentini, F.
    Dieci, M. V.
    Ficarra, G.
    Bettelli, S.
    Conte, P.
    Guarneri, V.
    [J]. CANCER RESEARCH, 2011, 71
  • [25] Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients
    Arslan, U. Y.
    Turker, I.
    Aksoy, S.
    Oksuzoglu, B.
    Helvaci, K.
    Ozdemir, N. Yildirim
    Uyeturk, U.
    Sonmez, O. Uysal
    Budakoglu, B.
    Zengin, N.
    [J]. JOURNAL OF BUON, 2013, 18 (03): : 585 - 593
  • [26] HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
    Alison E. Smith
    Emanuela Ferraro
    Anton Safonov
    Cristina Bernado Morales
    Enrique J. Arenas Lahuerta
    Qing Li
    Amanda Kulick
    Dara Ross
    David B. Solit
    Elisa de Stanchina
    Jorge Reis-Filho
    Neal Rosen
    Joaquín Arribas
    Pedram Razavi
    Sarat Chandarlapaty
    [J]. Nature Communications, 12
  • [27] Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
    Bradbury, Michelle
    Savard, Marie-France
    Vandermeer, Lisa
    Clemons, Lucas
    Pond, Gregory
    Hilton, John
    Clemons, Mark
    Mcgee, Sharon
    [J]. CURRENT ONCOLOGY, 2023, 30 (12) : 10477 - 10487
  • [28] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Kadri Altundag
    [J]. Breast Cancer Research and Treatment, 2019, 175 : 261 - 261
  • [29] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Altundag, Kadri
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 261 - 261
  • [30] Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer Patients
    You, Ji Young
    Park, Kyoung Hwa
    Lee, Eun Sook
    Kwon, Youngmee
    Kim, Kyoung Tae
    Nam, Seungyoon
    Kim, Dong Hee
    Bae, Jeoung Won
    [J]. CANCER CONTROL, 2023, 30
12345